ArticleDiscover oncology2026
The effects of Palbociclib and Ferulic acid combination on cellular processes in breast cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Breast cancer remains a major cause of cancer-related morbidity and mortality worldwide, highlighting the urgent need for novel therapeutic approaches. In this study, we aimed to investigate the combined effects of Palbociclib (PLB), a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, and Ferulic Acid (FA), a natural antioxidant, on breast cancer cells (MCF-7 and MDA-MB231) as well as on non-tumorigenic breast epithelial cells (MCF-10 A). To this end, the effects of PLB and FA on cell viability, migration, cell cycle progression, oxidative stress, endoplasmic reticulum (ER) stress, mitochondrial membrane potential (MMP), and apoptosis were evaluated. MTT assay results demonstrated that both agents, alone and in combination, significantly suppressed proliferation in cancer cells, whereas their impact on MCF-10 A cells was comparatively limited. In addition, oxidative stress and lipid peroxidation levels increased markedly in cancer cells following the combination treatment, while this increase was relatively restricted in MCF-10 A cells. MMP was significantly reduced in cancer cell lines under combination treatment, but was largely preserved in MCF-10 A cells. Molecular analyses revealed upregulation of ER stress markers (PERK, ATF-6, CHOP, IRE1, GRP78) and pro-apoptotic genes (BAX, Caspases, CYC-C), along with downregulation of the anti-apoptotic gene BCL-2. Furthermore, phosphorylated retinoblastoma protein (pRB) levels decreased significantly, indicating enhanced cell cycle arrest and chemosensitivity. Taken together, these findings suggest that the combination of PLB and FA exerts a anti-cancer effect by simultaneously inducing oxidative and ER stress, disrupting mitochondrial integrity, and promoting apoptosis in breast cancer cells, while sparing non-tumorigenic cells. This selective cytotoxicity underscores the therapeutic potential of PLB and FA as a promising combinational strategy for breast cancer treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.